We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01347788
Recruitment Status : Completed
First Posted : May 4, 2011
Results First Posted : November 17, 2015
Last Update Posted : November 28, 2016
Sponsor:
Information provided by (Responsible Party):

Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Prostate Adenocarcinoma
Intervention: Drug: cabozantinib

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Dose Level 0 Cabozantinib 40 mg daily
Dose Level -1 Cabozantinib 20 mg daily
Expansion Cohort Cabozantinib 40 mg daily

Participant Flow:   Overall Study
    Dose Level 0   Dose Level -1   Expansion Cohort
STARTED   11   10   13 
COMPLETED   11   10   13 
NOT COMPLETED   0   0   0 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
See Lee et al CCR 2013

Reporting Groups
  Description
Cabozantinib

Final results have been published Clin Cancer Res. 2013 Jun 1;19(11):3088-94. doi: 10.1158/1078-0432.CCR-13-0319. Epub 2013 Apr 3.

A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.

Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR.

Author information Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA. rjlee@partners.org


Baseline Measures
   Cabozantinib 
Overall Participants Analyzed 
[Units: Participants]
 34 
Age 
[Units: Years]
Median (Full Range)
 66 
 (48 to 83) 
Age 
[Units: Participants]
 
<=18 years   0 
Between 18 and 65 years   24 
>=65 years   10 
Gender 
[Units: Participants]
 
Female   0 
Male   34 
Region of Enrollment 
[Units: Participants]
 
United States   34 


  Outcome Measures

1.  Primary:   Partial Response in Bone Scan From Baseline to Week 6   [ Time Frame: Baseline and Week 6 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR. Clin Cancer Res. 2013 Jun 1;19(11):3088-94. doi: 10.1158/1078-0432.CCR-13-0319. Epub 2013 Apr 3.


  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Matthew R Smith, MDPhD
Organization: Massachusetts General Hospital
phone: 617-763-3748
e-mail: smith.matthew@mgh.harvard.edu


Publications of Results:

Responsible Party: Matthew R. Smith, MD, PhD, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01347788     History of Changes
Other Study ID Numbers: 11-005
First Submitted: April 11, 2011
First Posted: May 4, 2011
Results First Submitted: September 15, 2014
Results First Posted: November 17, 2015
Last Update Posted: November 28, 2016